Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Genetic alterations and epigenetic alterations of cancer-associated fibroblasts.

Du H, Che G.

Oncol Lett. 2017 Jan;13(1):3-12. doi: 10.3892/ol.2016.5451. Epub 2016 Nov 30.

2.

Phemindole, a Synthetic Di-indole Derivative Maneuvers the Store Operated Calcium Entry (SOCE) to Induce Potent Anti-Carcinogenic Activity in Human Triple Negative Breast Cancer Cells.

Chakraborty S, Ghosh S, Banerjee B, Santra A, Adhikary A, Misra AK, Sen PC.

Front Pharmacol. 2016 May 4;7:114. doi: 10.3389/fphar.2016.00114. eCollection 2016.

3.

Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations.

Bianchi-Frias D, Basom R, Delrow JJ, Coleman IM, Dakhova O, Qu X, Fang M, Franco OE, Ericson NG, Bielas JH, Hayward SW, True L, Morrissey C, Brown L, Bhowmick NA, Rowley D, Ittmann M, Nelson PS.

Mol Cancer Res. 2016 Apr;14(4):374-84. doi: 10.1158/1541-7786.MCR-15-0330. Epub 2016 Jan 11.

4.

Ex vivo behaviour of human bone tumor endothelial cells.

Infante T, Cesario E, Gallo M, Fazioli F, De Chiara A, Tutucci C, Apice G, de Nigris F.

Cancers (Basel). 2013 Apr 11;5(2):404-17. doi: 10.3390/cancers5020404.

5.

Cancer Stem Cells, EMT, and Developmental Pathway Activation in Pancreatic Tumors.

Hindriksen S, Bijlsma MF.

Cancers (Basel). 2012 Oct 12;4(4):989-1035. doi: 10.3390/cancers4040989.

6.

Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine.

Rivenbark AG, O'Connor SM, Coleman WB.

Am J Pathol. 2013 Oct;183(4):1113-1124. doi: 10.1016/j.ajpath.2013.08.002. Epub 2013 Aug 27. Review.

7.

Transformation of somatic cells into stem cell-like cells under a stromal niche.

Lee ST, Gong SP, Yum KE, Lee EJ, Lee CH, Choi JH, Kim DY, Han H, Kim KS, Hysolli E, Ahn JY, Park IH, Han JY, Jeong JW, Lim JM.

FASEB J. 2013 Jul;27(7):2644-56. doi: 10.1096/fj.12-223065. Epub 2013 Apr 11.

8.

Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.

Verma M, Khoury MJ, Ioannidis JP.

Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):189-200. doi: 10.1158/1055-9965.EPI-12-1263. Epub 2012 Dec 14. Review.

9.

Identification of inhibitory scFv antibodies targeting fibroblast activation protein utilizing phage display functional screens.

Zhang J, Valianou M, Simmons H, Robinson MK, Lee HO, Mullins SR, Marasco WA, Adams GP, Weiner LM, Cheng JD.

FASEB J. 2013 Feb;27(2):581-9. doi: 10.1096/fj.12-210377. Epub 2012 Oct 26.

10.

Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1α, autophagy and ketone body production.

Salem AF, Howell A, Sartini M, Sotgia F, Lisanti MP.

Cell Cycle. 2012 Nov 15;11(22):4167-73. doi: 10.4161/cc.22316. Epub 2012 Oct 9.

11.

In vivo evolution of tumor-derived endothelial cells.

McGuire TF, Sajithlal GB, Lu J, Nicholls RD, Prochownik EV.

PLoS One. 2012;7(5):e37138. doi: 10.1371/journal.pone.0037138. Epub 2012 May 18.

12.

Microenvironmental genomic alterations reveal signaling networks for head and neck squamous cell carcinoma.

Bebek G, Orloff M, Eng C.

J Clin Bioinforma. 2011 Aug 2;1(1):21. doi: 10.1186/2043-9113-1-21.

13.

Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas.

Skandalis SS, Labropoulou VT, Ravazoula P, Likaki-Karatza E, Dobra K, Kalofonos HP, Karamanos NK, Theocharis AD.

BMC Cancer. 2011 Jul 26;11:314. doi: 10.1186/1471-2407-11-314.

14.

Pten in the breast tumor microenvironment: modeling tumor-stroma coevolution.

Wallace JA, Li F, Leone G, Ostrowski MC.

Cancer Res. 2011 Feb 15;71(4):1203-7. doi: 10.1158/0008-5472.CAN-10-3263. Epub 2011 Feb 8. Review.

15.

HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype.

Gilbert PM, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KK, Welm AL, Feldman MD, Weber BL, Weaver VM.

J Clin Invest. 2010 May;120(5):1535-50. doi: 10.1172/JCI39534. Epub 2010 Apr 12.

16.

Cancer associated fibroblasts (CAFs) in tumor microenvironment.

Xing F, Saidou J, Watabe K.

Front Biosci (Landmark Ed). 2010 Jan 1;15:166-79. Review.

17.

Preinvasive breast cancer.

Sgroi DC.

Annu Rev Pathol. 2010;5:193-221. doi: 10.1146/annurev.pathol.4.110807.092306. Review.

18.

CXCR4 and matrix metalloproteinase-1 are elevated in breast carcinoma-associated fibroblasts and in normal mammary fibroblasts exposed to factors secreted by breast cancer cells.

Eck SM, Côté AL, Winkelman WD, Brinckerhoff CE.

Mol Cancer Res. 2009 Jul;7(7):1033-44. doi: 10.1158/1541-7786.MCR-09-0015. Epub 2009 Jul 7.

19.

Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts.

Sadlonova A, Bowe DB, Novak Z, Mukherjee S, Duncan VE, Page GP, Frost AR.

Cancer Microenviron. 2009 Dec;2(1):9-21. doi: 10.1007/s12307-008-0017-0. Epub 2009 Mar 18.

20.

Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies.

Kelemen LE, Couch FJ, Ahmed S, Dunning AM, Pharoah PD, Easton DF, Fredericksen ZS, Vierkant RA, Pankratz VS, Goode EL, Scott CG, Rider DN, Wang X, Cerhan JR, Vachon CM.

Breast Cancer Res. 2008;10(6):R98. doi: 10.1186/bcr2201. Epub 2008 Nov 26.

Supplemental Content

Support Center